Don Lehr

Net worth: 780 283 $ as of 2024-03-30

49 year

Health Technology

Consumer Services

Profile

Donald P.
Lehr is currently the Chief Executive Officer & Secretary at Genten Therapeutics, Inc. He is also the Secretary & Chief Legal Officer at Precigen, Inc. since 2009.
Previously, he served as the President, Treasurer & Director at GenVec, Inc. Mr. Lehr holds a graduate degree from The Johns Hopkins University, an undergraduate degree from Swarthmore College, and a graduate degree from The University of Maryland Francis King Carey School of Law.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
PRECIGEN INC 0.22%	2024-04-04	538,126 ( 0.22% )	780 283 $	2024-03-30

Don Lehr active positions

Companies	Position	Start
PRECIGEN, INC.	General Counsel	2008-12-31
Genten Therapeutics, Inc. Genten Therapeutics, Inc. BiotechnologyHealth Technology Genten Therapeutics, Inc. operates as a biotechnology firm. It delivers a monotherapy through an antigen-specific induction of immune tolerance for gluten to address unmet medical need. The company is headquartered in San Francisco, CA.	Chief Executive Officer	-

All active positions of Don Lehr

Former positions of Don Lehr

Companies	Position	End
GENVEC INC	President	-

See the detail of Don Lehr's experience

Training of Don Lehr

The Johns Hopkins University	Graduate Degree
Swarthmore College	Undergraduate Degree
The University of Maryland Francis King Carey School of Law	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Don Lehr's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PRECIGEN, INC.	Health Technology

Private companies	2
GenVec, Inc. GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD.	Health Technology
Genten Therapeutics, Inc. Genten Therapeutics, Inc. BiotechnologyHealth Technology Genten Therapeutics, Inc. operates as a biotechnology firm. It delivers a monotherapy through an antigen-specific induction of immune tolerance for gluten to address unmet medical need. The company is headquartered in San Francisco, CA.	Health Technology